Cantor Fitzgerald Reaffirms Overweight Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Cantor Fitzgerald restated their overweight rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report released on Thursday, Benzinga reports. They currently have a $7.00 price objective on the stock.

TSHA has been the subject of several other research reports. JMP Securities reaffirmed a market outperform rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, March 20th. Chardan Capital upped their price target on Taysha Gene Therapies from $5.00 to $7.00 and gave the company a buy rating in a report on Thursday, March 21st. Canaccord Genuity Group reaffirmed a buy rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Needham & Company LLC reaffirmed a buy rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, April 11th. Finally, Piper Sandler began coverage on Taysha Gene Therapies in a report on Tuesday, April 9th. They issued an overweight rating and a $9.00 price target for the company. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies has an average rating of Buy and an average price target of $6.88.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA opened at $2.41 on Thursday. Taysha Gene Therapies has a twelve month low of $0.50 and a twelve month high of $3.89. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.08 and a quick ratio of 4.08. The stock has a 50-day simple moving average of $2.55 and a 200 day simple moving average of $2.10.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Tuesday, March 19th. The company reported $0.35 EPS for the quarter. The firm had revenue of $3.60 million during the quarter, compared to analyst estimates of $4.75 million. On average, research analysts forecast that Taysha Gene Therapies will post -0.39 EPS for the current fiscal year.

Institutional Investors Weigh In On Taysha Gene Therapies

Several large investors have recently modified their holdings of the stock. FMR LLC grew its stake in shares of Taysha Gene Therapies by 2,035.0% in the 3rd quarter. FMR LLC now owns 24,527,801 shares of the company’s stock valued at $77,508,000 after purchasing an additional 23,378,974 shares during the period. RA Capital Management L.P. bought a new stake in Taysha Gene Therapies during the 3rd quarter worth approximately $58,373,000. RTW Investments LP bought a new stake in Taysha Gene Therapies during the 3rd quarter worth approximately $53,382,000. Vanguard Group Inc. grew its position in Taysha Gene Therapies by 16.3% during the 4th quarter. Vanguard Group Inc. now owns 6,195,567 shares of the company’s stock worth $10,966,000 after acquiring an additional 867,703 shares during the last quarter. Finally, Avoro Capital Advisors LLC grew its position in Taysha Gene Therapies by 11.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 4,355,555 shares of the company’s stock worth $7,709,000 after acquiring an additional 430,555 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.